Eli Lilly's pill version of orforglipron (Foundayo) beat Novo Nordisk's semaglutide pill at lowering blood sugar and weight loss in three large diabetes trials. Foundayo showed bigger drops in A1C levels and weight compared to the competing drug.

• •Orforglipron (Foundayo) showed superior A1C control vs semaglutide pill in three pivotal type 2 diabetes trials
• •Foundayo also showed greater weight loss than the competing semaglutide pill
• •Data came from three separate pivotal trials per Eli Lilly press release

Eli Lilly's Foundayo (orforglipron), an oral weight-loss drug you can take with food or water, helped women lose significant weight in two trials. Women in perimenopause lost up to 30.4 pounds, and those past menopause lost up to 28.2 pounds.

• •Foundayo (orforglipron) can be taken without food or water restrictions
• •Women in perimenopause lost up to 30.4 pounds in trial data
• •Women past menopause lost up to 28.2 pounds

Eli Lilly's new weight-loss pill Foundayo helped older adults lose up to 13% of their body weight in a large trial. The drug is taken once daily without needing to avoid food or water first.

• •Foundayo (orforglipron) linked to up to 13% body weight reduction in adults 65 and older
• •Analysis drawn from ATTAIN-1 and ATTAIN-2 trials
• •Drug is taken once daily with no food or water restrictions

Eli Lilly's obesity pill reached nearly 6,000 prescriptions in its third week on the market. The quick uptake shows strong early demand for the company's weight-loss drug.

• •Lilly's obesity pill hit nearly 6,000 prescriptions in week three after launch